

PRODUCT SPOTLIGHT

CELL LINES FOR ENHANCED VIRUS PRODUCTION

3 OPTIONS FOR ENHANCED VIRUS PRODUCTION – SAVE TIME AND MONEY!

- 2 cell lines optimized for vaccine manufacturing
- 1 cell line optimized for gene therapy delivery
- Superior clinical virus or AAV yields compared to parental lines
- 10 to 30-fold higher virus yields possible
- Broad applicability for basic research or industrial scale manufacturing
- Gene-edited for precise and stable STAT1 and STAT1/BAX knockouts
- Similar growth profiles to the parental cell lines
- Scalable for large- to small-scale production
- ATCC quality and performance

Table 1: Available Cell Lines for Enhanced Virus Production

Gene knockout	ATCC® No.	Designation	Function
STAT1	CCL-34-VHG™	MDCK.STAT1 KO	Viral vaccine production Virus propagation; production of high-titer viral stocks Viral vector transfection and viral particle production
STAT1	CCL-81-VHG™	Vero.STAT1 KO	Viral vaccine production Virus propagation; production of high-titer viral stocks Viral vector transfection and viral particle production
STAT1, BAX	CRL-1573-VHG™	293.STAT1 BAX KO	Gene therapy Transfection host Virus propagation; production of high-titer viral stocks




Figure 1: ATCC CRISPR-edited virus-producing cell lines show superior virus yields compared to parental cell lines. Staining of TCID₅₀ of viral supernatants from MDCK. STAT1 KO, Vero. STAT1 KO, and 293. STAT1 BAX KO show a 10-fold increase in Influenza A virus production, Dengue II virus production, and Sendai virus production over their respective parental cell lines.




Figure 2: ATCC CRISPR-edited virus-producing cell lines show increase virus genome copy number compared to parental cell lines. Staining of TCID₅₀ of viral supernatants from MDCK. STAT1 KO, Vero. STAT1 KO, and 293. STAT1 BAX KO show a 2-fold increase in Influenza A virus production, a 30-fold increase in Dengue II virus production, and a 1.8-fold increase Sendai virus production over their respective parental cell lines.

The continual spread of deadly viruses necessitates the development of novel prevention and treatment options. However, the development of a new antiviral vaccine can be challenged by low-yielding manufacturing processes.

Additionally, while adeno-associated virus (AAV) vectors are a commonly used platform for the delivery of gene therapies, a bottleneck in the process is scaling viral production.

To address these issues, ATCC used cutting-edge CRISPR/Cas9 gene-editing technology to develop STAT1 knockout or STAT1/BAX double knockout cell lines capable of producing high-titer viral stocks. Discover how these advanced biological models can be used in your vaccine and gene therapeutic development projects.

DISCOVER MORE AT WWW.ATCC.ORG/VACCINE

10801 University Boulevard
Manassas, Virginia 20110-2209

703.365.2700

703.365.2701

sales@atcc.org

www.atcc.org

CB-052025-v03

©2025 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services or to manufacture commercial products without prior ATCC written approval.